Literature DB >> 19922750

Application of nanotechnologies for improved immune response against infectious diseases in the developing world.

Michael Look1, Arunima Bandyopadhyay, Jeremy S Blum, Tarek M Fahmy.   

Abstract

There is an urgent need for new strategies to combat infectious diseases in developing countries. Many pathogens have evolved to elude immunity and this has limited the utility of current therapies. Additionally, the emergence of co-infections and drug resistant pathogens has increased the need for advanced therapeutic and diagnostic strategies. These challenges can be addressed with therapies that boost the quality and magnitude of an immune response in a predictable, designable fashion that can be applied for wide-spread use. Here, we discuss how biomaterials and specifically nanoscale delivery vehicles can be used to modify and improve the immune system response against infectious diseases. Immunotherapy of infectious disease is the enhancement or modulation of the immune system response to more effectively prevent or clear pathogen infection. Nanoscale vehicles are particularly adept at facilitating immunotherapeutic approaches because they can be engineered to have different physical properties, encapsulated agents, and surface ligands. Additionally, nanoscaled point-of-care diagnostics offer new alternatives for portable and sensitive health monitoring that can guide the use of nanoscale immunotherapies. By exploiting the unique tunability of nanoscale biomaterials to activate, shape, and detect immune system effector function, it may be possible in the near future to generate practical strategies for the prevention and treatment of infectious diseases in the developing world. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19922750      PMCID: PMC2880812          DOI: 10.1016/j.addr.2009.11.011

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  190 in total

1.  Combined interferon and lamivudine therapy: is this the treatment of choice for patients with chronic hepatitis B virus infection?

Authors:  N A Terrault
Journal:  Hepatology       Date:  2000-09       Impact factor: 17.425

Review 2.  Alternative activation of macrophages: an immunologic functional perspective.

Authors:  Fernando O Martinez; Laura Helming; Siamon Gordon
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

3.  Drug-resistant TB and HIV in resource-limited settings: what TB/HIV programmes can learn from each other.

Authors:  R Colebunders; W Worodria; E Jones-López; M Joloba; L Apers; J Ellner
Journal:  Trop Med Int Health       Date:  2008-07-28       Impact factor: 2.622

4.  Cure of experimental Chagas' disease by the bis-triazole DO870 incorporated into 'stealth' polyethyleneglycol-polylactide nanospheres.

Authors:  J Molina; J Urbina; R Gref; Z Brener
Journal:  J Antimicrob Chemother       Date:  2001-01       Impact factor: 5.790

5.  Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting.

Authors:  Tarek M Fahmy; Robert M Samstein; Casey C Harness; W Mark Saltzman
Journal:  Biomaterials       Date:  2005-04-18       Impact factor: 12.479

6.  rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo.

Authors:  B J Johnson; L G Bekker; R Rickman; S Brown; M Lesser; S Ress; P Willcox; L Steyn; G Kaplan
Journal:  Tuber Lung Dis       Date:  1997

Review 7.  IL-15 is a growth factor and an activator of CD8 memory T cells.

Authors:  Nan-Ping Weng; Kebin Liu; Marta Catalfamo; Yu Li; Pierre A Henkart
Journal:  Ann N Y Acad Sci       Date:  2002-12       Impact factor: 5.691

Review 8.  Dendritic cells and C-type lectin receptors: coupling innate to adaptive immune responses.

Authors:  Sandra J van Vliet; Juan J García-Vallejo; Yvette van Kooyk
Journal:  Immunol Cell Biol       Date:  2008-08-05       Impact factor: 5.126

9.  Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection.

Authors:  J A Whittum-Hudson; L L An; W M Saltzman; R A Prendergast; A B MacDonald
Journal:  Nat Med       Date:  1996-10       Impact factor: 53.440

10.  Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity.

Authors:  Samar Hamdy; Ommoleila Molavi; Zengshuan Ma; Azita Haddadi; Aws Alshamsan; Zahra Gobti; Sara Elhasi; John Samuel; Afsaneh Lavasanifar
Journal:  Vaccine       Date:  2008-08-03       Impact factor: 3.641

View more
  21 in total

Review 1.  Applications of nanomaterials as vaccine adjuvants.

Authors:  Motao Zhu; Rongfu Wang; Guangjun Nie
Journal:  Hum Vaccin Immunother       Date:  2014-11-17       Impact factor: 3.452

Review 2.  Veterinary vaccine nanotechnology: pulmonary and nasal delivery in livestock animals.

Authors:  Daniella Calderon-Nieva; Kalhari Bandara Goonewardene; Susantha Gomis; Marianna Foldvari
Journal:  Drug Deliv Transl Res       Date:  2017-08       Impact factor: 4.617

3.  An isoniazid analogue promotes Mycobacterium tuberculosis-nanoparticle interactions and enhances bacterial killing by macrophages.

Authors:  Tatiany J de Faria; Mariane Roman; Nicole M de Souza; Rodrigo De Vecchi; João Vitor de Assis; Ana Lúcia Gomes dos Santos; Ivan H Bechtold; Nathalie Winter; Maurilio José Soares; Luciano Paulino Silva; Mauro V De Almeida; André Báfica
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

4.  Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype.

Authors:  Stacey L Demento; Weiguo Cui; Jason M Criscione; Eric Stern; Jacob Tulipan; Susan M Kaech; Tarek M Fahmy
Journal:  Biomaterials       Date:  2012-04-06       Impact factor: 12.479

Review 5.  Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses.

Authors:  Moses O Oyewumi; Amit Kumar; Zhengrong Cui
Journal:  Expert Rev Vaccines       Date:  2010-09       Impact factor: 5.217

6.  Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice.

Authors:  Michael Look; Eric Stern; Qin A Wang; Leah D DiPlacido; Michael Kashgarian; Joe Craft; Tarek M Fahmy
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

7.  The nanomaterial-dependent modulation of dendritic cells and its potential influence on therapeutic immunosuppression in lupus.

Authors:  Michael Look; W Mark Saltzman; Joe Craft; Tarek M Fahmy
Journal:  Biomaterials       Date:  2013-11-01       Impact factor: 12.479

Review 8.  Advancements in protein nanoparticle vaccine platforms to combat infectious disease.

Authors:  Nina Butkovich; Enya Li; Aaron Ramirez; Amanda M Burkhardt; Szu-Wen Wang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-11-08

Review 9.  Strategies to Use Nanoparticles to Generate CD4 and CD8 Regulatory T Cells for the Treatment of SLE and Other Autoimmune Diseases.

Authors:  David A Horwitz; Sean Bickerton; Antonio La Cava
Journal:  Front Immunol       Date:  2021-06-15       Impact factor: 7.561

Review 10.  Nanostructured porous Si-based nanoparticles for targeted drug delivery.

Authors:  Mohammad-Ali Shahbazi; Barbara Herranz; Hélder A Santos
Journal:  Biomatter       Date:  2012 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.